nodes	percent_of_prediction	percent_of_DWPC	metapath
Sucralfate—EGF—breast cancer	0.579	0.924	CbGaD
Sucralfate—ALB—breast cancer	0.0475	0.0758	CbGaD
Sucralfate—FGB—mammary gland—breast cancer	0.00583	0.0732	CbGeAlD
Sucralfate—Venous thrombosis—Carboplatin—breast cancer	0.00477	0.059	CcSEcCtD
Sucralfate—Fluid overload—Carboplatin—breast cancer	0.00414	0.0512	CcSEcCtD
Sucralfate—FGB—embryo—breast cancer	0.00398	0.05	CbGeAlD
Sucralfate—EGF—mammary gland—breast cancer	0.00364	0.0458	CbGeAlD
Sucralfate—PGA5—female reproductive system—breast cancer	0.00355	0.0446	CbGeAlD
Sucralfate—FGA—embryo—breast cancer	0.0034	0.0428	CbGeAlD
Sucralfate—FGF2—mammary gland—breast cancer	0.00321	0.0404	CbGeAlD
Sucralfate—Venous thrombosis—Letrozole—breast cancer	0.00319	0.0395	CcSEcCtD
Sucralfate—FGG—adrenal gland—breast cancer	0.00305	0.0383	CbGeAlD
Sucralfate—Extravasation—Carboplatin—breast cancer	0.00295	0.0365	CcSEcCtD
Sucralfate—FGG—female gonad—breast cancer	0.00284	0.0357	CbGeAlD
Sucralfate—Fluid overload—Idarubicin—breast cancer	0.00263	0.0325	CcSEcCtD
Sucralfate—EGF—embryo—breast cancer	0.00249	0.0312	CbGeAlD
Sucralfate—FGB—female reproductive system—breast cancer	0.00241	0.0303	CbGeAlD
Sucralfate—FGB—bone marrow—breast cancer	0.00228	0.0286	CbGeAlD
Sucralfate—FGA—pituitary gland—breast cancer	0.00225	0.0283	CbGeAlD
Sucralfate—FGB—female gonad—breast cancer	0.00219	0.0276	CbGeAlD
Sucralfate—Phlebitis—Carboplatin—breast cancer	0.00217	0.0268	CcSEcCtD
Sucralfate—FGA—female reproductive system—breast cancer	0.00206	0.0259	CbGeAlD
Sucralfate—FGB—endocrine gland—breast cancer	0.00204	0.0256	CbGeAlD
Sucralfate—EGF—epithelium—breast cancer	0.00203	0.0255	CbGeAlD
Sucralfate—FGA—bone marrow—breast cancer	0.00195	0.0245	CbGeAlD
Sucralfate—EGF—skin of body—breast cancer	0.00193	0.0242	CbGeAlD
Sucralfate—FGA—female gonad—breast cancer	0.00188	0.0236	CbGeAlD
Sucralfate—Extravasation—Idarubicin—breast cancer	0.00187	0.0232	CcSEcCtD
Sucralfate—FGG—lymph node—breast cancer	0.00183	0.023	CbGeAlD
Sucralfate—EGF—endometrium—breast cancer	0.00182	0.0229	CbGeAlD
Sucralfate—FGA—endocrine gland—breast cancer	0.00175	0.0219	CbGeAlD
Sucralfate—EGF—uterus—breast cancer	0.00168	0.0211	CbGeAlD
Sucralfate—EGF—pituitary gland—breast cancer	0.00165	0.0207	CbGeAlD
Sucralfate—FGF2—endometrium—breast cancer	0.00161	0.0202	CbGeAlD
Sucralfate—EGF—female reproductive system—breast cancer	0.00151	0.0189	CbGeAlD
Sucralfate—FGF2—uterus—breast cancer	0.00148	0.0186	CbGeAlD
Sucralfate—EGF—adrenal gland—breast cancer	0.00147	0.0185	CbGeAlD
Sucralfate—FGF2—pituitary gland—breast cancer	0.00145	0.0183	CbGeAlD
Sucralfate—Phlebitis—Letrozole—breast cancer	0.00145	0.018	CcSEcCtD
Sucralfate—FGF2—adipose tissue—breast cancer	0.00145	0.0182	CbGeAlD
Sucralfate—Lung disorder—Vinorelbine—breast cancer	0.00142	0.0176	CcSEcCtD
Sucralfate—Extravasation—Vinblastine—breast cancer	0.00139	0.0172	CcSEcCtD
Sucralfate—Phlebitis—Idarubicin—breast cancer	0.00138	0.017	CcSEcCtD
Sucralfate—EGF—female gonad—breast cancer	0.00137	0.0172	CbGeAlD
Sucralfate—Hyponatraemia—Ixabepilone—breast cancer	0.00133	0.0165	CcSEcCtD
Sucralfate—Extravasation—Melphalan—breast cancer	0.00132	0.0164	CcSEcCtD
Sucralfate—FGF2—adrenal gland—breast cancer	0.0013	0.0163	CbGeAlD
Sucralfate—Extravasation—Goserelin—breast cancer	0.00129	0.016	CcSEcCtD
Sucralfate—EGF—endocrine gland—breast cancer	0.00128	0.016	CbGeAlD
Sucralfate—ALB—mammary gland—breast cancer	0.00126	0.0158	CbGeAlD
Sucralfate—Venous thrombosis—Paclitaxel—breast cancer	0.00126	0.0155	CcSEcCtD
Sucralfate—FGF2—female gonad—breast cancer	0.00121	0.0152	CbGeAlD
Sucralfate—Lung disorder—Irinotecan—breast cancer	0.00117	0.0145	CcSEcCtD
Sucralfate—Extravasation—Vinorelbine—breast cancer	0.00116	0.0143	CcSEcCtD
Sucralfate—Extravasation—Thiotepa—breast cancer	0.0011	0.0137	CcSEcCtD
Sucralfate—Venous thrombosis—Capecitabine—breast cancer	0.00103	0.0128	CcSEcCtD
Sucralfate—Phlebitis—Vinblastine—breast cancer	0.00102	0.0126	CcSEcCtD
Sucralfate—Extravasation—Mitoxantrone—breast cancer	0.000953	0.0118	CcSEcCtD
Sucralfate—Extravasation—Irinotecan—breast cancer	0.000953	0.0118	CcSEcCtD
Sucralfate—Extravasation—Gemcitabine—breast cancer	0.000928	0.0115	CcSEcCtD
Sucralfate—Extravasation—Fluorouracil—breast cancer	0.000913	0.0113	CcSEcCtD
Sucralfate—Infection—Carboplatin—breast cancer	0.000912	0.0113	CcSEcCtD
Sucralfate—EGF—lymph node—breast cancer	0.000882	0.0111	CbGeAlD
Sucralfate—Infection—Lapatinib—breast cancer	0.00086	0.0106	CcSEcCtD
Sucralfate—Phlebitis—Vinorelbine—breast cancer	0.00085	0.0105	CcSEcCtD
Sucralfate—Hyponatraemia—Melphalan—breast cancer	0.000841	0.0104	CcSEcCtD
Sucralfate—Infection—Fulvestrant—breast cancer	0.000791	0.00979	CcSEcCtD
Sucralfate—Oedema—Toremifene—breast cancer	0.000786	0.00972	CcSEcCtD
Sucralfate—FGF2—lymph node—breast cancer	0.000778	0.00977	CbGeAlD
Sucralfate—Extravasation—Paclitaxel—breast cancer	0.000777	0.00962	CcSEcCtD
Sucralfate—Hyponatraemia—Vinorelbine—breast cancer	0.000735	0.00909	CcSEcCtD
Sucralfate—Body temperature increased—Carboplatin—breast cancer	0.000726	0.00898	CcSEcCtD
Sucralfate—Venous thrombosis—Epirubicin—breast cancer	0.000718	0.00889	CcSEcCtD
Sucralfate—Phlebitis—Mitoxantrone—breast cancer	0.000701	0.00867	CcSEcCtD
Sucralfate—Oedema—Exemestane—breast cancer	0.000692	0.00856	CcSEcCtD
Sucralfate—Infection—Exemestane—breast cancer	0.000687	0.0085	CcSEcCtD
Sucralfate—Venous thrombosis—Doxorubicin—breast cancer	0.000665	0.00822	CcSEcCtD
Sucralfate—Extravasation—Docetaxel—breast cancer	0.000659	0.00815	CcSEcCtD
Sucralfate—Oedema—Ixabepilone—breast cancer	0.000653	0.00807	CcSEcCtD
Sucralfate—Infection—Ixabepilone—breast cancer	0.000648	0.00802	CcSEcCtD
Sucralfate—Body temperature increased—Fulvestrant—breast cancer	0.000629	0.00779	CcSEcCtD
Sucralfate—Oedema—Letrozole—breast cancer	0.000615	0.0076	CcSEcCtD
Sucralfate—Oedema—Anastrozole—breast cancer	0.000615	0.0076	CcSEcCtD
Sucralfate—Infection—Anastrozole—breast cancer	0.000611	0.00755	CcSEcCtD
Sucralfate—Infection—Letrozole—breast cancer	0.000611	0.00755	CcSEcCtD
Sucralfate—Hyponatraemia—Irinotecan—breast cancer	0.000606	0.0075	CcSEcCtD
Sucralfate—Hyponatraemia—Mitoxantrone—breast cancer	0.000606	0.0075	CcSEcCtD
Sucralfate—Lung disorder—Methotrexate—breast cancer	0.000585	0.00724	CcSEcCtD
Sucralfate—Infection—Raloxifene—breast cancer	0.000579	0.00717	CcSEcCtD
Sucralfate—Infection—Idarubicin—breast cancer	0.000579	0.00717	CcSEcCtD
Sucralfate—Phlebitis—Paclitaxel—breast cancer	0.000571	0.00707	CcSEcCtD
Sucralfate—Lung disorder—Epirubicin—breast cancer	0.000548	0.00678	CcSEcCtD
Sucralfate—Body temperature increased—Exemestane—breast cancer	0.000547	0.00676	CcSEcCtD
Sucralfate—Body temperature increased—Ixabepilone—breast cancer	0.000516	0.00638	CcSEcCtD
Sucralfate—ALB—adrenal gland—breast cancer	0.000508	0.00639	CbGeAlD
Sucralfate—Lung disorder—Doxorubicin—breast cancer	0.000507	0.00627	CcSEcCtD
Sucralfate—Hyponatraemia—Paclitaxel—breast cancer	0.000494	0.00611	CcSEcCtD
Sucralfate—Body temperature increased—Anastrozole—breast cancer	0.000486	0.00601	CcSEcCtD
Sucralfate—Body temperature increased—Letrozole—breast cancer	0.000486	0.00601	CcSEcCtD
Sucralfate—Phlebitis—Docetaxel—breast cancer	0.000484	0.00599	CcSEcCtD
Sucralfate—Extravasation—Methotrexate—breast cancer	0.000475	0.00587	CcSEcCtD
Sucralfate—Infection—Chlorambucil—breast cancer	0.000469	0.00581	CcSEcCtD
Sucralfate—Phlebitis—Capecitabine—breast cancer	0.000469	0.0058	CcSEcCtD
Sucralfate—Body temperature increased—Raloxifene—breast cancer	0.000461	0.0057	CcSEcCtD
Sucralfate—Body temperature increased—Idarubicin—breast cancer	0.000461	0.0057	CcSEcCtD
Sucralfate—Extravasation—Epirubicin—breast cancer	0.000444	0.0055	CcSEcCtD
Sucralfate—Oedema—Tamoxifen—breast cancer	0.000421	0.0052	CcSEcCtD
Sucralfate—Hyponatraemia—Docetaxel—breast cancer	0.000419	0.00518	CcSEcCtD
Sucralfate—Infection—Tamoxifen—breast cancer	0.000418	0.00517	CcSEcCtD
Sucralfate—Oedema—Melphalan—breast cancer	0.000412	0.00509	CcSEcCtD
Sucralfate—Extravasation—Doxorubicin—breast cancer	0.000411	0.00509	CcSEcCtD
Sucralfate—Infection—Melphalan—breast cancer	0.000409	0.00506	CcSEcCtD
Sucralfate—Hyponatraemia—Capecitabine—breast cancer	0.000406	0.00502	CcSEcCtD
Sucralfate—Oedema—Goserelin—breast cancer	0.000402	0.00497	CcSEcCtD
Sucralfate—Infection—Goserelin—breast cancer	0.000399	0.00494	CcSEcCtD
Sucralfate—Body temperature increased—Chlorambucil—breast cancer	0.000373	0.00462	CcSEcCtD
Sucralfate—Infection—Vinorelbine—breast cancer	0.000357	0.00442	CcSEcCtD
Sucralfate—Infection—Thiotepa—breast cancer	0.000341	0.00422	CcSEcCtD
Sucralfate—Phlebitis—Epirubicin—breast cancer	0.000327	0.00404	CcSEcCtD
Sucralfate—Body temperature increased—Goserelin—breast cancer	0.000318	0.00393	CcSEcCtD
Sucralfate—ALB—lymph node—breast cancer	0.000305	0.00383	CbGeAlD
Sucralfate—Phlebitis—Doxorubicin—breast cancer	0.000302	0.00374	CcSEcCtD
Sucralfate—Oedema—Mitoxantrone—breast cancer	0.000297	0.00367	CcSEcCtD
Sucralfate—Oedema—Irinotecan—breast cancer	0.000297	0.00367	CcSEcCtD
Sucralfate—Infection—Mitoxantrone—breast cancer	0.000295	0.00365	CcSEcCtD
Sucralfate—Infection—Irinotecan—breast cancer	0.000295	0.00365	CcSEcCtD
Sucralfate—Oedema—Gemcitabine—breast cancer	0.000289	0.00357	CcSEcCtD
Sucralfate—Infection—Gemcitabine—breast cancer	0.000287	0.00355	CcSEcCtD
Sucralfate—Body temperature increased—Vinorelbine—breast cancer	0.000284	0.00352	CcSEcCtD
Sucralfate—Oedema—Fluorouracil—breast cancer	0.000284	0.00352	CcSEcCtD
Sucralfate—Hyponatraemia—Epirubicin—breast cancer	0.000283	0.0035	CcSEcCtD
Sucralfate—Infection—Fluorouracil—breast cancer	0.000282	0.00349	CcSEcCtD
Sucralfate—Body temperature increased—Thiotepa—breast cancer	0.000272	0.00336	CcSEcCtD
Sucralfate—Hyponatraemia—Doxorubicin—breast cancer	0.000261	0.00323	CcSEcCtD
Sucralfate—Oedema—Paclitaxel—breast cancer	0.000242	0.00299	CcSEcCtD
Sucralfate—Infection—Paclitaxel—breast cancer	0.00024	0.00297	CcSEcCtD
Sucralfate—Body temperature increased—Mitoxantrone—breast cancer	0.000235	0.0029	CcSEcCtD
Sucralfate—Body temperature increased—Irinotecan—breast cancer	0.000235	0.0029	CcSEcCtD
Sucralfate—Body temperature increased—Gemcitabine—breast cancer	0.000228	0.00283	CcSEcCtD
Sucralfate—Body temperature increased—Fluorouracil—breast cancer	0.000225	0.00278	CcSEcCtD
Sucralfate—Oedema—Docetaxel—breast cancer	0.000205	0.00254	CcSEcCtD
Sucralfate—Infection—Docetaxel—breast cancer	0.000204	0.00252	CcSEcCtD
Sucralfate—Oedema—Capecitabine—breast cancer	0.000199	0.00246	CcSEcCtD
Sucralfate—Infection—Capecitabine—breast cancer	0.000197	0.00244	CcSEcCtD
Sucralfate—Body temperature increased—Paclitaxel—breast cancer	0.000191	0.00237	CcSEcCtD
Sucralfate—Body temperature increased—Docetaxel—breast cancer	0.000162	0.00201	CcSEcCtD
Sucralfate—Body temperature increased—Capecitabine—breast cancer	0.000157	0.00194	CcSEcCtD
Sucralfate—Infection—Methotrexate—breast cancer	0.000147	0.00182	CcSEcCtD
Sucralfate—Oedema—Epirubicin—breast cancer	0.000138	0.00171	CcSEcCtD
Sucralfate—Infection—Epirubicin—breast cancer	0.000137	0.0017	CcSEcCtD
Sucralfate—Oedema—Doxorubicin—breast cancer	0.000128	0.00158	CcSEcCtD
Sucralfate—Infection—Doxorubicin—breast cancer	0.000127	0.00157	CcSEcCtD
Sucralfate—Body temperature increased—Methotrexate—breast cancer	0.000117	0.00145	CcSEcCtD
Sucralfate—Body temperature increased—Epirubicin—breast cancer	0.000109	0.00135	CcSEcCtD
Sucralfate—Body temperature increased—Doxorubicin—breast cancer	0.000101	0.00125	CcSEcCtD
Sucralfate—EGF—Signaling Pathways—RELA—breast cancer	3.4e-06	1.6e-05	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—MMP1—breast cancer	3.39e-06	1.59e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—GPX4—breast cancer	3.39e-06	1.59e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—SULT1A1—breast cancer	3.39e-06	1.59e-05	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—ERBB2—breast cancer	3.38e-06	1.59e-05	CbGpPWpGaD
Sucralfate—FGF2—Immune System—IFNG—breast cancer	3.37e-06	1.58e-05	CbGpPWpGaD
Sucralfate—FGF2—Immune System—MDM2—breast cancer	3.35e-06	1.57e-05	CbGpPWpGaD
Sucralfate—EGF—Disease—EGFR—breast cancer	3.34e-06	1.57e-05	CbGpPWpGaD
Sucralfate—FGF2—Immune System—RAF1—breast cancer	3.34e-06	1.57e-05	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—MTOR—breast cancer	3.33e-06	1.57e-05	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—PIK3CB—breast cancer	3.33e-06	1.57e-05	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—CDK2—breast cancer	3.33e-06	1.56e-05	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—PLAU—breast cancer	3.33e-06	1.56e-05	CbGpPWpGaD
Sucralfate—FGF2—Immune System—RELA—breast cancer	3.33e-06	1.56e-05	CbGpPWpGaD
Sucralfate—FGB—Signaling Pathways—PIK3CA—breast cancer	3.32e-06	1.56e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—IDH1—breast cancer	3.31e-06	1.55e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—GSTA1—breast cancer	3.31e-06	1.55e-05	CbGpPWpGaD
Sucralfate—FGF2—Immune System—ERBB2—breast cancer	3.31e-06	1.55e-05	CbGpPWpGaD
Sucralfate—FGF2—Adaptive Immune System—PIK3CA—breast cancer	3.28e-06	1.54e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—NAT2—breast cancer	3.27e-06	1.54e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—TERT—breast cancer	3.27e-06	1.53e-05	CbGpPWpGaD
Sucralfate—FGF2—Disease—NOS3—breast cancer	3.26e-06	1.53e-05	CbGpPWpGaD
Sucralfate—FGF2—Immune System—MTOR—breast cancer	3.26e-06	1.53e-05	CbGpPWpGaD
Sucralfate—FGF2—Immune System—PIK3CB—breast cancer	3.26e-06	1.53e-05	CbGpPWpGaD
Sucralfate—FGF2—Immune System—CD4—breast cancer	3.26e-06	1.53e-05	CbGpPWpGaD
Sucralfate—FGG—Signaling Pathways—PIK3CA—breast cancer	3.26e-06	1.53e-05	CbGpPWpGaD
Sucralfate—FGA—Signaling Pathways—PIK3CA—breast cancer	3.26e-06	1.53e-05	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—CAV1—breast cancer	3.25e-06	1.53e-05	CbGpPWpGaD
Sucralfate—ALB—Platelet activation, signaling and aggregation—MAPK3—breast cancer	3.25e-06	1.53e-05	CbGpPWpGaD
Sucralfate—FGB—Signaling Pathways—TP53—breast cancer	3.22e-06	1.51e-05	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—CXCL8—breast cancer	3.2e-06	1.5e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—FGFR1—breast cancer	3.17e-06	1.49e-05	CbGpPWpGaD
Sucralfate—FGF2—Innate Immune System—HRAS—breast cancer	3.16e-06	1.48e-05	CbGpPWpGaD
Sucralfate—FGF2—Developmental Biology—AKT1—breast cancer	3.16e-06	1.48e-05	CbGpPWpGaD
Sucralfate—EGF—Disease—KRAS—breast cancer	3.16e-06	1.48e-05	CbGpPWpGaD
Sucralfate—ALB—Platelet activation, signaling and aggregation—TGFB1—breast cancer	3.15e-06	1.48e-05	CbGpPWpGaD
Sucralfate—FGG—Signaling Pathways—TP53—breast cancer	3.15e-06	1.48e-05	CbGpPWpGaD
Sucralfate—FGA—Signaling Pathways—TP53—breast cancer	3.15e-06	1.48e-05	CbGpPWpGaD
Sucralfate—EGF—Immune System—PIK3CA—breast cancer	3.14e-06	1.48e-05	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—CDKN1B—breast cancer	3.13e-06	1.47e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—HIF1A—breast cancer	3.13e-06	1.47e-05	CbGpPWpGaD
Sucralfate—FGF2—Disease—MDM2—breast cancer	3.1e-06	1.45e-05	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—FN1—breast cancer	3.09e-06	1.45e-05	CbGpPWpGaD
Sucralfate—FGF2—Disease—RAF1—breast cancer	3.09e-06	1.45e-05	CbGpPWpGaD
Sucralfate—FGB—Signaling Pathways—HRAS—breast cancer	3.07e-06	1.44e-05	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—CASP3—breast cancer	3.07e-06	1.44e-05	CbGpPWpGaD
Sucralfate—FGF2—Immune System—CDKN1B—breast cancer	3.06e-06	1.44e-05	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—IL2—breast cancer	3.06e-06	1.44e-05	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—NOS2—breast cancer	3.06e-06	1.44e-05	CbGpPWpGaD
Sucralfate—FGF2—Disease—ERBB2—breast cancer	3.05e-06	1.43e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—LEP—breast cancer	3.05e-06	1.43e-05	CbGpPWpGaD
Sucralfate—FGF2—Adaptive Immune System—HRAS—breast cancer	3.03e-06	1.42e-05	CbGpPWpGaD
Sucralfate—FGF2—Innate Immune System—IL6—breast cancer	3.02e-06	1.42e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—CAV1—breast cancer	3.02e-06	1.42e-05	CbGpPWpGaD
Sucralfate—FGF2—Disease—MTOR—breast cancer	3.01e-06	1.41e-05	CbGpPWpGaD
Sucralfate—FGF2—Disease—PIK3CB—breast cancer	3.01e-06	1.41e-05	CbGpPWpGaD
Sucralfate—FGG—Signaling Pathways—HRAS—breast cancer	3.01e-06	1.41e-05	CbGpPWpGaD
Sucralfate—FGA—Signaling Pathways—HRAS—breast cancer	3.01e-06	1.41e-05	CbGpPWpGaD
Sucralfate—FGF2—Immune System—IL1B—breast cancer	3.01e-06	1.41e-05	CbGpPWpGaD
Sucralfate—FGF2—Disease—CD4—breast cancer	3.01e-06	1.41e-05	CbGpPWpGaD
Sucralfate—FGF2—Immune System—IL2—breast cancer	3e-06	1.41e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—KDR—breast cancer	2.99e-06	1.4e-05	CbGpPWpGaD
Sucralfate—FGF2—Disease—PTGS2—breast cancer	2.98e-06	1.4e-05	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—CCND1—breast cancer	2.98e-06	1.4e-05	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—JUN—breast cancer	2.98e-06	1.4e-05	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—PIK3CG—breast cancer	2.96e-06	1.39e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism of lipids and lipoproteins—CAV1—breast cancer	2.96e-06	1.39e-05	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—CTNNB1—breast cancer	2.96e-06	1.39e-05	CbGpPWpGaD
Sucralfate—FGB—Signaling Pathways—IL6—breast cancer	2.94e-06	1.38e-05	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—EGF—breast cancer	2.93e-06	1.37e-05	CbGpPWpGaD
Sucralfate—FGF2—Immune System—JUN—breast cancer	2.92e-06	1.37e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—ESR1—breast cancer	2.91e-06	1.37e-05	CbGpPWpGaD
Sucralfate—EGF—Immune System—HRAS—breast cancer	2.91e-06	1.37e-05	CbGpPWpGaD
Sucralfate—EGF—Disease—PIK3CA—breast cancer	2.9e-06	1.36e-05	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—MMP9—breast cancer	2.9e-06	1.36e-05	CbGpPWpGaD
Sucralfate—FGF2—Immune System—CTNNB1—breast cancer	2.89e-06	1.36e-05	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—CDKN1A—breast cancer	2.89e-06	1.36e-05	CbGpPWpGaD
Sucralfate—FGG—Signaling Pathways—IL6—breast cancer	2.88e-06	1.35e-05	CbGpPWpGaD
Sucralfate—FGA—Signaling Pathways—IL6—breast cancer	2.88e-06	1.35e-05	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—PTEN—breast cancer	2.88e-06	1.35e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—FN1—breast cancer	2.88e-06	1.35e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—DPYD—breast cancer	2.87e-06	1.35e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—MED12—breast cancer	2.87e-06	1.35e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—NFKBIA—breast cancer	2.84e-06	1.33e-05	CbGpPWpGaD
Sucralfate—FGF2—Disease—CDKN1B—breast cancer	2.83e-06	1.33e-05	CbGpPWpGaD
Sucralfate—FGF2—Immune System—CDKN1A—breast cancer	2.83e-06	1.33e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—ALDOA—breast cancer	2.83e-06	1.33e-05	CbGpPWpGaD
Sucralfate—FGF2—Immune System—PTEN—breast cancer	2.82e-06	1.32e-05	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—MAPK8—breast cancer	2.82e-06	1.32e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—NOTCH1—breast cancer	2.82e-06	1.32e-05	CbGpPWpGaD
Sucralfate—FGF2—Innate Immune System—AKT1—breast cancer	2.79e-06	1.31e-05	CbGpPWpGaD
Sucralfate—EGF—Immune System—IL6—breast cancer	2.78e-06	1.31e-05	CbGpPWpGaD
Sucralfate—FGF2—Immune System—MAPK8—breast cancer	2.76e-06	1.29e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—PIK3CG—breast cancer	2.75e-06	1.29e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—APC—breast cancer	2.75e-06	1.29e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—KIT—breast cancer	2.75e-06	1.29e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—NCOA3—breast cancer	2.74e-06	1.29e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—SLC2A2—breast cancer	2.72e-06	1.28e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—EGF—breast cancer	2.72e-06	1.28e-05	CbGpPWpGaD
Sucralfate—FGB—Signaling Pathways—AKT1—breast cancer	2.72e-06	1.27e-05	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—IGF1—breast cancer	2.71e-06	1.27e-05	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—AKT2—breast cancer	2.71e-06	1.27e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism of lipids and lipoproteins—PIK3CG—breast cancer	2.7e-06	1.27e-05	CbGpPWpGaD
Sucralfate—EGF—Disease—HRAS—breast cancer	2.68e-06	1.26e-05	CbGpPWpGaD
Sucralfate—ALB—Platelet activation, signaling and aggregation—PIK3CA—breast cancer	2.68e-06	1.26e-05	CbGpPWpGaD
Sucralfate—FGF2—Adaptive Immune System—AKT1—breast cancer	2.68e-06	1.26e-05	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—SRC—breast cancer	2.67e-06	1.25e-05	CbGpPWpGaD
Sucralfate—FGF2—Disease—CTNNB1—breast cancer	2.67e-06	1.25e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—CPT1A—breast cancer	2.67e-06	1.25e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—MTR—breast cancer	2.67e-06	1.25e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—ABCG2—breast cancer	2.67e-06	1.25e-05	CbGpPWpGaD
Sucralfate—FGG—Signaling Pathways—AKT1—breast cancer	2.66e-06	1.25e-05	CbGpPWpGaD
Sucralfate—FGA—Signaling Pathways—AKT1—breast cancer	2.66e-06	1.25e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—HPGDS—breast cancer	2.62e-06	1.23e-05	CbGpPWpGaD
Sucralfate—FGF2—Immune System—SRC—breast cancer	2.61e-06	1.23e-05	CbGpPWpGaD
Sucralfate—FGF2—Disease—CDKN1A—breast cancer	2.61e-06	1.22e-05	CbGpPWpGaD
Sucralfate—FGF2—Disease—PTEN—breast cancer	2.6e-06	1.22e-05	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—PIK3CD—breast cancer	2.6e-06	1.22e-05	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—VEGFA—breast cancer	2.6e-06	1.22e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—HBA1—breast cancer	2.6e-06	1.22e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—BRAF—breast cancer	2.59e-06	1.21e-05	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—STAT3—breast cancer	2.58e-06	1.21e-05	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—SERPINE1—breast cancer	2.57e-06	1.21e-05	CbGpPWpGaD
Sucralfate—EGF—Disease—IL6—breast cancer	2.57e-06	1.21e-05	CbGpPWpGaD
Sucralfate—EGF—Immune System—AKT1—breast cancer	2.57e-06	1.21e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—ACHE—breast cancer	2.54e-06	1.19e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—GSTT1—breast cancer	2.54e-06	1.19e-05	CbGpPWpGaD
Sucralfate—FGF2—Immune System—STAT3—breast cancer	2.52e-06	1.18e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—IGF1—breast cancer	2.52e-06	1.18e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—AKT2—breast cancer	2.52e-06	1.18e-05	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—MAPK3—breast cancer	2.46e-06	1.16e-05	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—NOS3—breast cancer	2.46e-06	1.15e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—PIK3CD—breast cancer	2.42e-06	1.14e-05	CbGpPWpGaD
Sucralfate—FGF2—Disease—SRC—breast cancer	2.41e-06	1.13e-05	CbGpPWpGaD
Sucralfate—FGF2—Immune System—MAPK3—breast cancer	2.41e-06	1.13e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—CYP17A1—breast cancer	2.4e-06	1.13e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—SERPINE1—breast cancer	2.39e-06	1.12e-05	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—MYC—breast cancer	2.39e-06	1.12e-05	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—TGFB1—breast cancer	2.39e-06	1.12e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—ENO1—breast cancer	2.38e-06	1.12e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—PTGS1—breast cancer	2.38e-06	1.12e-05	CbGpPWpGaD
Sucralfate—EGF—Disease—AKT1—breast cancer	2.37e-06	1.11e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism of lipids and lipoproteins—PIK3CD—breast cancer	2.37e-06	1.11e-05	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—EGFR—breast cancer	2.34e-06	1.1e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—CYP2D6—breast cancer	2.33e-06	1.1e-05	CbGpPWpGaD
Sucralfate—FGF2—Disease—STAT3—breast cancer	2.33e-06	1.09e-05	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—RAF1—breast cancer	2.32e-06	1.09e-05	CbGpPWpGaD
Sucralfate—FGF2—Immune System—EGFR—breast cancer	2.29e-06	1.08e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—NCOA2—breast cancer	2.29e-06	1.07e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—NOS3—breast cancer	2.29e-06	1.07e-05	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—PIK3CB—breast cancer	2.27e-06	1.07e-05	CbGpPWpGaD
Sucralfate—FGF2—Disease—MAPK3—breast cancer	2.22e-06	1.04e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—FASN—breast cancer	2.22e-06	1.04e-05	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—KRAS—breast cancer	2.21e-06	1.04e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—BCHE—breast cancer	2.21e-06	1.04e-05	CbGpPWpGaD
Sucralfate—ALB—Platelet activation, signaling and aggregation—AKT1—breast cancer	2.19e-06	1.03e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—SLC5A5—breast cancer	2.18e-06	1.03e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—MDM2—breast cancer	2.17e-06	1.02e-05	CbGpPWpGaD
Sucralfate—FGF2—Immune System—KRAS—breast cancer	2.17e-06	1.02e-05	CbGpPWpGaD
Sucralfate—FGF2—Disease—MYC—breast cancer	2.16e-06	1.02e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—RAF1—breast cancer	2.16e-06	1.01e-05	CbGpPWpGaD
Sucralfate—FGF2—Disease—TGFB1—breast cancer	2.16e-06	1.01e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—RELA—breast cancer	2.15e-06	1.01e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—ERBB2—breast cancer	2.14e-06	1e-05	CbGpPWpGaD
Sucralfate—FGF2—Disease—EGFR—breast cancer	2.12e-06	9.93e-06	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—PIK3CB—breast cancer	2.11e-06	9.9e-06	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—MTOR—breast cancer	2.11e-06	9.9e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—NQO1—breast cancer	2.11e-06	9.9e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—SLC2A1—breast cancer	2.11e-06	9.9e-06	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—IL2—breast cancer	2.08e-06	9.78e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism of lipids and lipoproteins—PIK3CB—breast cancer	2.07e-06	9.7e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—CYP3A4—breast cancer	2.06e-06	9.66e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism of lipids and lipoproteins—PTGS2—breast cancer	2.05e-06	9.61e-06	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—PIK3CA—breast cancer	2.03e-06	9.54e-06	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—CXCL8—breast cancer	2.03e-06	9.52e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—CYP1B1—breast cancer	2.02e-06	9.5e-06	CbGpPWpGaD
Sucralfate—ALB—Transmembrane transport of small molecules—RAF1—breast cancer	2.01e-06	9.45e-06	CbGpPWpGaD
Sucralfate—FGF2—Disease—KRAS—breast cancer	2e-06	9.38e-06	CbGpPWpGaD
Sucralfate—FGF2—Immune System—PIK3CA—breast cancer	1.99e-06	9.34e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—HSP90AA1—breast cancer	1.98e-06	9.31e-06	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—CDKN1B—breast cancer	1.98e-06	9.3e-06	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—TP53—breast cancer	1.97e-06	9.23e-06	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—CASP3—breast cancer	1.94e-06	9.11e-06	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—IL2—breast cancer	1.94e-06	9.1e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—NCOA1—breast cancer	1.93e-06	9.06e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—CYP19A1—breast cancer	1.9e-06	8.93e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—STK11—breast cancer	1.9e-06	8.93e-06	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—CCND1—breast cancer	1.89e-06	8.87e-06	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—JUN—breast cancer	1.88e-06	8.85e-06	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—HRAS—breast cancer	1.88e-06	8.83e-06	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—CTNNB1—breast cancer	1.87e-06	8.78e-06	CbGpPWpGaD
Sucralfate—FGF2—Immune System—HRAS—breast cancer	1.84e-06	8.64e-06	CbGpPWpGaD
Sucralfate—FGF2—Disease—PIK3CA—breast cancer	1.84e-06	8.62e-06	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—MMP9—breast cancer	1.83e-06	8.61e-06	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—CDKN1A—breast cancer	1.83e-06	8.58e-06	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—PTEN—breast cancer	1.82e-06	8.56e-06	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—SRC—breast cancer	1.82e-06	8.54e-06	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—IL6—breast cancer	1.8e-06	8.45e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism of lipids and lipoproteins—PTEN—breast cancer	1.78e-06	8.38e-06	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—MAPK8—breast cancer	1.78e-06	8.37e-06	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—VEGFA—breast cancer	1.77e-06	8.31e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—COMT—breast cancer	1.77e-06	8.3e-06	CbGpPWpGaD
Sucralfate—FGF2—Immune System—IL6—breast cancer	1.76e-06	8.27e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—GSTP1—breast cancer	1.76e-06	8.26e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—HMOX1—breast cancer	1.74e-06	8.15e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—ITPR1—breast cancer	1.73e-06	8.13e-06	CbGpPWpGaD
Sucralfate—FGF2—Disease—HRAS—breast cancer	1.7e-06	7.98e-06	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—SRC—breast cancer	1.69e-06	7.94e-06	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—MAPK3—breast cancer	1.68e-06	7.87e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—ABCB1—breast cancer	1.67e-06	7.82e-06	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—AKT1—breast cancer	1.66e-06	7.79e-06	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—VEGFA—breast cancer	1.65e-06	7.73e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—TYMS—breast cancer	1.64e-06	7.68e-06	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—STAT3—breast cancer	1.63e-06	7.65e-06	CbGpPWpGaD
Sucralfate—FGF2—Disease—IL6—breast cancer	1.63e-06	7.63e-06	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—TGFB1—breast cancer	1.63e-06	7.63e-06	CbGpPWpGaD
Sucralfate—FGF2—Immune System—AKT1—breast cancer	1.62e-06	7.63e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—NCOR1—breast cancer	1.62e-06	7.59e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—GSTM1—breast cancer	1.62e-06	7.59e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—PLA2G4A—breast cancer	1.62e-06	7.59e-06	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—MAPK3—breast cancer	1.56e-06	7.31e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—GPX1—breast cancer	1.55e-06	7.27e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—CYP1A1—breast cancer	1.53e-06	7.2e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—ERCC2—breast cancer	1.52e-06	7.14e-06	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—MYC—breast cancer	1.51e-06	7.11e-06	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—TGFB1—breast cancer	1.51e-06	7.1e-06	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—KRAS—breast cancer	1.51e-06	7.07e-06	CbGpPWpGaD
Sucralfate—FGF2—Disease—AKT1—breast cancer	1.5e-06	7.04e-06	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—EGFR—breast cancer	1.48e-06	6.96e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—MTHFR—breast cancer	1.43e-06	6.71e-06	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—KRAS—breast cancer	1.4e-06	6.57e-06	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—PIK3CA—breast cancer	1.38e-06	6.49e-06	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—TP53—breast cancer	1.34e-06	6.28e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—CAV1—breast cancer	1.32e-06	6.19e-06	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—PIK3CA—breast cancer	1.29e-06	6.04e-06	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—HRAS—breast cancer	1.28e-06	6.01e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	1.26e-06	5.91e-06	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—TP53—breast cancer	1.24e-06	5.84e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—PIK3CG—breast cancer	1.2e-06	5.64e-06	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—HRAS—breast cancer	1.19e-06	5.59e-06	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—IL6—breast cancer	1.14e-06	5.35e-06	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—AKT1—breast cancer	1.13e-06	5.3e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—PIK3CD—breast cancer	1.06e-06	4.96e-06	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—AKT1—breast cancer	1.05e-06	4.93e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—NOS3—breast cancer	9.97e-07	4.68e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—PIK3CB—breast cancer	9.2e-07	4.32e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—PTGS2—breast cancer	9.12e-07	4.28e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—PTEN—breast cancer	7.95e-07	3.73e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—PIK3CA—breast cancer	5.61e-07	2.63e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—AKT1—breast cancer	4.58e-07	2.15e-06	CbGpPWpGaD
